Allergan and Actress Shay Mitchell Join Forces to Inspire Women to Know Their Birth Control
Allergan plc (NYSE: AGN), a leader in women's healthcare and the maker of Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), today announced the launch of 'BC Trivia' featuring actress and new ambassador Shay Mitchell - a fun and engaging trivia quiz designed to educate young women about contraceptive options in a familiar way for its bold educational platform, Know Your Birth Control®.
In partnership with Allergan, Mitchell, known as one of the top names in the industry for her roles in several acclaimed movies and television shows, hopes to encourage women to have candid conversations about their contraceptive options with their healthcare providers, while simultaneously offering preliminary education.
"In conversations with my friends and family, it is constantly made clear to me that people are not speaking about birth control as much as they should be. When they do, the dialogue is riddled with misconceptions," said Mitchell. "At the very least, we should all know about the host of options that are available to us. Through my partnership with Allergan and Know Your Birth Control®, I hope we can bridge that gap together. It all starts by getting informed, talking to your doctor, and not being afraid to ask questions."
Launching last year, the program continues to evolve with new partners who are excited to contribute to the birth control conversation by offering informative facts and tips.
"In my practice, it is a consistent norm that birth control will be widely used, yet poorly understood," said Dr. Lakeisha Richardson, MD, a Mississipi-based OB/GYN and paid consultant of Allergan. "I always advocate that no question is too small when it comes to helping a patient make decisions about what is right for them. Through my upcoming work with Allergan, I look forward to channeling this approach, and to developing materials and resources that will help support women seeking information about contraceptive options."
On Mitchell's partnership with Know Your Birth Control®, Cindy Schwartz, Associate Vice President of Marketing at Allergan Women's Healthcare said, "We are delighted that Shay is joining us in this significant campaign. With her support and participation, we feel strongly that we will reach a wide network of women, encouraging many to take the initiative to speak to their doctors, and ultimately be in control of their birth control decisions."
To watch the quiz featuring Shay Mitchell, and to learn more about Know Your Birth Control®, visit www.KnowYourBirthControl.com.
What is Lo Loestrin® Fe?
IMPORTANT RISK INFORMATION
WARNING TO WOMEN WHO SMOKE Do not use Lo Loestrin Fe if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots, or stroke. This risk increases with age and the number of cigarettes you smoke. ---------------------------------------
Who should not take Lo Loestrin Fe?
What else should I know about taking Lo Loestrin Fe?
What are the most serious risks of taking Lo Loestrin Fe?
What are the possible side effects of Lo Loestrin Fe?
Birth control pills do not protect you against any sexually transmitted disease, including HIV, the virus that causes AIDS.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/allergan-and-actress-shay-mitchell-join-forces-to-inspire-women-to-know-their-birth-control-300661374.html
SOURCE Allergan plc
Company Codes: NYSE:AGN